ASCO 2015 Highlights

Bavituximab: a Novel, Investigational Immunotherapy Agent Targeting Phosphatidylserine in the Vasculature of the Tumor Microenvironment

Mechanism of Action Magnifier – 2016 Desk Reference

Alectinib: an Anaplastic Lymphoma Kinase (ALK) Inhibitor

Mechanism of Action Magnifier – 2016 Desk Reference

Lenvatinib: a Receptor Tyrosine Kinase Inhibitor

Mechanism of Action Magnifier – 2016 Desk Reference

Abemaciclib (LY2835219): a Dual Inhibitor of CDK4 and CDK6

Mechanism of Action Magnifier – 2016 Desk Reference

Venetoclax (ABT-199): a Selective Inhibitor of B-Cell Lymphoma-2

Mechanism of Action Magnifier – 2016 Desk Reference

Ruxolitinib: a Kinase Inhibitor That Inhibits Overactive JAK Pathway Signaling

Mechanism of Action Magnifier – 2016 Desk Reference

Panobinostat: a Histone Deacetylase Inhibitor

Mechanism of Action Magnifier – 2016 Desk Reference

Idelalisib: a Selective Inhibitor of the Delta Isoform of Phosphatidylinositol 3-Kinase

Mechanism of Action Magnifier – 2016 Desk Reference

Ibrutinib: an Inhibitor of Bruton’s Tyrosine Kinase

Mechanism of Action Magnifier – 2016 Desk Reference

Duvelisib (IPI-145): a Dual Inhibitor of Phosphoinositide 3-Kinase (PI3K)-Delta and -Gamma

Mechanism of Action Magnifier – 2016 Desk Reference

Page 158 of 330